Drug Profile
Research programme: wound healing agents - AnaMar
Alternative Names: AM 220; Project AM 220 - ColModLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AnaMar Medical
- Developer AnaMar AB
- Class
- Mechanism of Action Collagen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Wounds in Sweden (Topical)
- 25 Jul 2008 Preclinical development is ongoing
- 25 Jul 2006 Preclinical trials in Wounds in Sweden (Topical)